American Academy of Allergy Asthma and Immunology/World Allergy Organization Joint Congress (AAAAI/WAO Joint Congress 2025)

Lebrikizumab improves anxiety and depression symptoms, as shown by PROMIS* scores, in patients with moderate-to-severe atopic dermatitis (AD), according to the ADore trial presented at AAAAI/WAO 2025.

Data presented at AAAAI/WAO 2025 verify the potential of the epinephrine sublingual film (ESF) Anaphylm for the treatment of type 1 allergic reactions, including anaphylaxis.

Eliminating certain foods such as egg and milk from children’s diet due to IgE-mediated allergy may hinder growth, but oral immunotherapy helps improve growth trajectories, especially when initiated at a younger age, according to two studies.

Twice-daily application of ruxolitinib cream appears effective and well tolerated in the treatment of mild-to-moderate atopic dermatitis (AD) regardless of age, based on a pooled analysis of three phase III trials presented at AAAAI/WAO 2025.

Treatment with two doses of depemokimab results in sufficient concentrations to adequately control blood eosinophil counts (BEC) over 1 year, as shown in the ANCHOR 1 and 2 trials. This finding suggests sustained anti-interleukin-5 (IL-5) biological effect and impact on type 2 inflammation.

Omalizumab remains superior to oral immunotherapy (OIT) for the treatment of multi-food allergies with fewer adverse effects in Stage 2 of the NIH*-sponsored phase III OUtMATCH** study, the first head-to-head trial comparing the two treatments.

The attainment of remission in EGPA is durable whether treated with benralizumab for 2 years or switched to benralizumab after 52 weeks of mepolizumab treatment, with additional merits observed among those who switched, as indicated in the OLE of MANDARA